Status: Recruiting

A Phase 1, First-in-Human Study of CITY-RBP4 in Healthy Volunteers and STGD1 Participants

This is a first-in-human (FIH), multicenter, randomized, double-masked, placebo-controlled adaptive clinical study evaluating the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) of CITY-RBP4, following single-ascending doses and multiple doses, via subcutaneous (SC) administration.

Participants needed: 48

Trial details

Phase: Phase 1Age: 12-45Biological sex: AllType: InterventionalSponsor: City TherapeuticsUpdated: Sep 23, 2026Locations: 1

Eligibility criteria

Willing and able to provide written informed consent form [+7]

Clinically significant ocular disease or prior ocular surgery that could interfe... [+18]

Status: Recruiting

An Observational Study in Subjects to Follow the Progression of Stargardt Disease Type 1 (STGD1) Caused by Bi-Allelic Autosomal Recessive Mutations in the ABCA4 Gene

This is an Observational Study to Follow the Progression of Stargardt Disease Type 1 (STGD1) Caused by Bi-Allelic Autosomal Recessive Mutations in the ABCA4 Gene This is a multicenter study which will enroll approximately 75 subjects

Participants needed: 75

Trial details

Age: 12-65Biological sex: AllType: ObservationalSponsor: Splice BioUpdated: Sep 19, 2025Locations: 20

Eligibility criteria

Provide written consent [+9]

Are an immediate family member (e.g., child, sibling) of the Sponsor or study si... [+10]